Lite Strategy, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Lite Strategy, Inc. (LITS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.64 per share for the 12-month period ending 2022-06-30, per its 10-K filed 2022-09-08.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2022-09-08
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-09-30 was $2.46, a 59.74% increase year-over-year.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-09-30 was $1.54, a 16.30% decline year-over-year.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-31 was $1.69.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-09-30 was $1.84, a 6.36% increase year-over-year.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.64, a 29.91% decline from fiscal 2021.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $2.34, a 32.20% increase from fiscal 2020.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $1.77, a 0.56% decline from fiscal 2019.
- Lite Strategy, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was $1.78, a 4.09% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2022-06-30 | $1.64 10-K · filed 2022-09-08 | |||
| 2022-03-31 | $1.64 10-Q · filed 2022-05-23 | |||
| 2021-12-31 | $2.09 10-Q/A · filed 2022-05-23 | |||
| 2021-06-30 | $2.34 10-K/A · filed 2022-05-23 | |||
| 2021-03-31 | $2.22 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $2.47 10-Q · filed 2021-02-04 | |||
| 2020-09-30 | $2.46 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $1.77 10-K · filed 2020-09-09 | |||
| 2020-03-31 | $1.54 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $1.54 10-Q · filed 2020-02-06 | |||
| 2019-09-30 | $1.54 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $1.78 10-K · filed 2019-08-28 | |||
| 2019-03-31 | $1.69 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $1.70 10-Q · filed 2019-02-07 | |||
| 2018-09-30 | $1.84 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $1.71 10-K · filed 2018-08-30 | |||
| 2018-03-31 | $1.66 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $1.66 10-Q · filed 2018-02-08 | |||
| 2017-09-30 | $1.73 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |